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Dehydrated hereditary stomatocytosis 1 or hereditary xerocytosis (HX, OMIM 194380) is a 
rare hereditary autosomal dominant disorder characterized by hemolytic anemia and red 
blood cell (RBC) dehydration. The occurrence of HX is linked with gain-of-function mutations 
in PIEZO1, the gene encoding for the mechanosensitive non-specific cation channel 
PIEZO1(1, 2) which is activated by shear-stress and in concert with other ion channels 
(particularly the Gardos potassium calcium-activated channel, KCNN4) regulates cell volume 
homeostasis and metabolic activity in the RBC(3). Intriguingly, PIEZO1 gain-of-function 
mutations have recently been reported to occur at a much higher frequency within the 
population than had been previously described and also implicated in malaria resistance(4), 
suggesting that the mechanisms underpinning HX may merit further investigation. Since 
reticulocytosis is one of the hallmarks of HX(5), we sought to determine whether altered 
reticulocyte maturation could be a causative agent of this phenotype. We characterize 
reticulocytes and erythrocytes from 10 HX patients in comparison to healthy controls, 
revealing alterations in deformability and vesicle content that implicate a maturational defect 
in HX. We further demonstrate that HX patients suffer from impaired reticulocyte maturation 
as assayed through differences in the extent and rate of loss of CD71 and RNA content over 
time and that this effect can be recapitulated in healthy reticulocytes upon chemically-
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induced PIEZO1 overactivation, providing a functional link to the reticulocytosis phenotype 
present in HX.  
A total of 10 samples were investigated in this study, constituting 9 patients from 6 families 
with one sample in duplicate. The corresponding hematological parameters can be found in 
Table 1. All patients under investigation suffered from mutations in PIEZO1, with the majority 
displaying reticulocytosis and abnormal mean cell volume values (MCV). Several patients 
also displayed anomalous serum ferritin content, which comprised both iron overload and 
deficiency. Moreover, 3 of the 9 patients had previously been subjected to splenectomy. 
Further detail on individual patients is provided in Supplemental Patient Case Histories.  
Splenectomy leads to a partial loss of the body’s quality assurance system for ensuring the 
removal of physiologically-altered circulating RBCs(6), the effects of which can be readily 
observed on the deformability index and cross-sectional area profiles obtained upon 
examination of the cells with the Automated Rheoscope and Cell Analyzer (ARCA)(7), 
shown in Figure 1A. Individual scatter plots for each sample are shown in Supplemental 
Figure 1. 
Both RBCs (CD71-) and reticulocytes (CD71+) from splenectomized PIEZO1-defective 
patients display decreased deformability (CD71- median DI of 1.33 [Interquartile range, IQR 
1.08-1.58], CD71+ median DI of 1.80 [IQR 1.61-1.99]) in comparison with non-
splenectomized patients (CD71- median DI of 1.70 [IQR 1.46-1.94], CD71+ median DI of 
1.91 [IQR 1.76-2.06]), with their RBCs displaying an enriched proportion of microcytic cells 
(Cross-sectional area = ~40 µm2). Interestingly, while RBCs from non-splenectomized 
patients also display lowered deformability and macrocytosis in comparison with reference 
values (ref: CD71- median DI of 1.94 [IQR 1.78-2.11]), their reticulocytes display a relatively 
normal deformability index profile (ref: CD71+ median DI of 1.93 [IQR 1.84-2.02]). Whilst a 
potential influence of CD71- reticulocytes on the total RBC population cannot be excluded, 
these results nonetheless illustrate that the effect of PIEZO1 overactivation on deformability 
only manifests in the transition from the reticulocyte to the RBC as defined by loss of CD71, 
implicating a potential defect in reticulocyte maturation of HX patients. 
Using mitochondrial content as a surrogate measure for intracellular vesicle content, as 
previously described(8), we proceeded to investigate whether physiological vesicle loss is 
altered in reticulocytes from HX patients, observing a marked increase in vesicle in both 
RBCs and reticulocytes from splenectomized HX patients (Figure 1B). Surprisingly, a 
significantly increased vesicle content is also observed in the RBCs from non-
splenectomized patients but not in their reticulocytes, once again indicating that defects 
occur in HX during reticulocyte transition to the RBC. 
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To investigate whether an alteration exists in reticulocyte maturation in HX, reticulocytes 
were isolated from patients and healthy donors and incubated in IMDM (supplemented as 
previously described(9)) at 37oC 5% CO2 for 7 days (168 hours), either alone or in co-culture 
by layering the reticulocytes onto MS-5 cells (murine stromal cell line). Transferrin receptor 
(CD71) expression and RNA content (as measured by thiazole orange, TO) was then 
examined by flow cytometry. Given that reticulocyte maturation normally occurs over a 
period of 24 to 48 hours after release in circulation(10), the time frame of the experiment was 
selected so as to ensure that the effects induced by incubation became saturating, that is, 
that the cells would have reached their maximum possible progression through the 
maturational process during the experimental conditions used. Co-culture with MS-5 cells 
was utilized in this study due to previously reported positive effects regarding the capacity of 
MS-5 cells, or of the microenvironment they generate, to facilitate reticulocyte maturation in 
vitro(11). The exact mechanism through which MS-5 co-culture induces partial reticulocyte 
maturation has not been reported as of yet; however, physical cell-cell interaction between 
MS-5 cells and reticulocytes could constitute one of the contributors to that mechanism. 
Importantly, since PIEZO1 channel activity (and thus mechanotransduction) is altered in HX 
patients, effects resulting from physical interaction could be disrupted. 
Representative examples of the CD71/TO loss exhibited during maturation by healthy 
controls and HX patients are shown in Figure 2A, comprising culture both with and without 
the presence of MS-5 cells. Delayed reduction in the levels of both markers is evident in HX 
patients, and especially so at the 24 and 48-hour timepoints; however, we also observed that 
cells from HX patients start the maturational process with higher levels of both CD71 
expression and RNA content, an observation that is consistent with the delayed erythroid 
differentiation recently reported in HX patients(12). Thus, the longer 168-hour timepoint is 
valuable from the perspective that a delay over the course of 48 hours or even longer would 
not disrupt the result achieved at the end of maturation. Progression through maturation also 
differs in both controls and patients depending on whether reticulocytes are co-cultured with 
MS-5 cells, with RNA being lost independently of co-culture and a more substantial reduction 
in CD71 content occurring in cells undergoing co-culture. Despite these differences, 
reticulocyte maturation is significantly delayed in HX patients irrespective of the method used 
for incubation (Figure 2B, Figure 2C). The percentage of cells negative for CD71 and RNA 
is significantly lower in HX patients after 7 days of incubation with both conditions, illustrating 
not only the existence of a delay in maturation but also an inability of patient reticulocytes to 
undergo complete maturation in this system.  
In order to investigate whether the observed effect was a direct consequence of PIEZO1 
over-activation, we examined whether this maturational phenotype could be recapitulated by 
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treating healthy reticulocytes with Yoda1 (a specific chemical activator of PIEZO1(13)) over 
an extended period of time, with the added advantage that this method enables the 
experiment to be initiated from a standpoint of identical starting CD71/TO profiles. We 
observe a significant delay in maturation rate (Figure 2D) upon treatment with 5 µM of 
Yoda1 which becomes less pronounced over time, likely due to compensatory mechanisms 
being engaged as a result of continuous PIEZO1 activation. The Yoda1 concentration in use 
was chosen due to constituting the maximal non-saturating concentration that induces 
calcium entry (Supplemental Figure 2). Notably, pharmacological treatment with 
FK506/Tacrolimus (a calcineurin inhibitor recently reported to abrogate Yoda1-induced 
effects in erythroblasts(12, 14)) did not ameliorate the delayed reticulocyte maturation 
phenotype of HX patients (Supplemental Figure 3). 
Since disrupted calcium homeostasis is a prominent consequence of PIEZO1 overactivity, 
we hypothesize that elevated intracellular calcium levels account for the observed defects in 
reticulocyte maturation. However, as calcium is also known to exert widespread influence on 
cell signaling processes, determining the specific underlying mechanism for the detrimental 
effects caused by overactive PIEZO1 is a challenging proposition. Nonetheless, this work 
provides the first evidence that overactivation of PIEZO1 impacts reticulocyte maturation. 
Further investigation of the interplay between PIEZO1 activity and that of other ion channels 
(as well as of downstream signaling pathways) is likely to be of interest for future studies. 
In conclusion, we report that hereditary xerocytosis patients with gain-of-function mutations 
in PIEZO1 suffer from multiple transcriptionally-independent effects caused by PIEZO1 
overactivation. These include delayed reticulocyte maturation as assayed by loss of CD71, 
RNA and intracellular vesicle content and significantly decreased capacity to deform upon 
completion of maturation, which is exacerbated in patients that have undergone 
splenectomy.  This delay in reticulocyte maturation can be recapitulated through chemical 
treatment with Yoda1, demonstrating that PIEZO1 overactivation has repercussions beyond 
impaired hydration and volume homeostasis in the erythrocyte. 
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Table 1: Hematological parameters of the Hereditary Xerocytosis patients under investigation 
Patient Age Gender Mutation Splenectomy Hemoglobin  (g/dL) 
MCV  
(fL) 
Reticulocyte no. 
(109/L) 
Reticulocyte 
% 
Ferritin  
(µg/L) 
1 33 M p.R2088G +  p.2169-2170 delK N 14.2 105 718 18.7 94 
2† 23 F p.R2456H Y 13.1 100 259 7.2 170 
3† 47 M p.R2456H N 16.8 93 997 20.0 107 
4 19 M p.V598M Y 16.1 106 472 11.0 591 
5‡ 47 F p.E2496ELE Y 10.2 77 227 5.0 67 
6‡ 47 F p.E2496ELE Y 12.5 74.4 113 2.6 ----- 
7 55 F p.V598M N 8.7 108 137 5.9 875 
8# 46 M p.R2456H N 13.5 97 700 18.4 175 
9# 43 F p.R2456H N 11.8 94 294 9.3 257 
10† 18 M p.R2456H N 9.83 80 402 11.0 17 
Reference values:  a [12-16] [80-94] [25-120] [0.8-3.0] [25-250] 
 
The patient numbers in the table are used to identify the respective samples in the reticulocyte maturation experiment shown in Figure 2B and Figure 2C. 
Patient age and gender are provided. “Mutation” identifies the PIEZO1 mutation(s) found in the patient. “Splenectomy” defines whether the patient has or has 
not undergone splenectomy. MCV: Mean Cell Volume (obtained through the use of a CELL-DYN Sapphire system or a Sysmex XN-9000 system). 
Reticulocyte no.: absolute reticulocyte number. Reticulocyte %: reticulocyte percentage as a function of all erythroid cells in circulation. Serum hemoglobin 
concentration and serum ferritin concentration values are also provided. Reference values are provided under each of the numerical columns. † and # 
indicate that the patients are relatives. ‡ indicates a repeat admission to the clinic (no serum ferritin concentration values were obtained for the second visit).
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Figure legends 
Figure 1: Cell defects arise upon reticulocyte maturation in Hereditary Xerocytosis 
patients 
A) Contour plots of cross-sectional area plotted against the deformability index (as 
measured by dividing cell length by cell width), visualizing the probability distribution of 
erythrocytes (CD71 negative) and reticulocytes (CD71 positive) from HX patients compared 
to healthy reference samples and separated by splenectomy status. The cells were 
subjected to magnetic cell isolation using CD71 MicroBeads [Miltenyi Biotec] for separation 
of the CD71 positive and negative populations. The cells were analyzed with the Automated 
Rheoscope and Cell Analyzer, as previously described(8), with a minimum of 1000 cells 
obtained per sample. The probability density functions were generated through kernel-
density estimation of data comprising 3 reference samples, 6 non-splenectomized patient 
samples and 4 splenectomized patient samples.  
B) Comparison of mitochondrial content in cells from HX patients compared to samples from 
healthy donors (control) in CD71 negative and CD71 positive cells, separated by 
splenectomy status. Tile scans composed of 10x10 images were taken at 1024x1024 
resolution of cells labelled with Mitotracker Deep Red [500nM, Thermo Fisher Scientific] 
using confocal imaging and analyzed manually. Sample numbers comprise 3 reference 
samples, 6 non-splenectomized patient samples and 4 splenectomized patient samples. 
Data are represented as mean ± SD. All comparisons were made with two-sample unequal 
variance (heteroscedastic) T-tests. n.s.s.: non-statistically significant; *: P < 0.05; ***: P < 
0.001. 
 
Figure 2: Delayed reticulocyte maturation is observed in HX and can be recapitulated 
through chemical activation of PIEZO1  
A) Representative flow cytometry diagram plotting RNA content (Thiazole Orange, TO) 
against membrane transferrin receptor (CD71) content (APC anti-human CD71 [CY1G4], 
Biolegend), displaying progression through reticulocyte maturation of cells isolated from a 
healthy donor (Ctrl) or an HX patient (PIEZO1-HX, patient no. 5) and kept in static cell 
culture conditions over the course of 168 hours (7 days), shown in magenta. Cells were 
either cultured alone or layered onto MS-5 cells for co-culture (details for MS-5 culture are as 
described in Darghouth et al(11)). CD71-negative cells from the respective samples are 
shown in green, defining the quadrant and respective limits of a CD71-/TO- population. 
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B) Loss of CD71/TO in reticulocytes cultured alone (left) or in co-culture with MS-5 cells 
(right) as measured by the percentage of cells present in the CD71-/TO- quadrant and 
normalized against the CD71-/TO- percentage observed in the final timepoint of healthy 
control samples. N = 7 for the control samples, with error bars showing standard deviation. 
Each patient is represented as one separate line above, with all patients averaged below 
(the error bars show standard deviation). In the bottom panel, all samples were normalized 
to the final timepoint of MS-5 co-cultured reticulocytes from the healthy control of their 
respective experiment. Co-culture data was not obtainable for patient number 6. The results 
from patient number 10 were extreme outliers and thus excluded from this figure (available 
on request). Notably, this patient presented with iron deficiency, a condition which has 
previously been reported to decrease phenotypic severity in HX(15).  
C) Average CD71/TO loss in reticulocytes from healthy donors and HX patients, cultured 
alone (blue) or in co-culture with MS-5 cells (red) and normalized against the CD71-/TO- 
percentage observed in the final timepoint of healthy control samples. Error bars show 
standard deviation. N = 7 for the control samples. All comparisons were made with two-
sample unequal variance (heteroscedastic) T-tests. ***: P-value < 0.001. 
D) Average CD71/TO loss in reticulocytes cultured alone (green) or in co-culture with MS-5 
cells (orange), with and without treatment with either 1:4000 DMSO (v/v) or 5 µM Yoda1 
(chemical inducer of PIEZO1 activity; Tocris Bioscience). The data comprises three 
biological replicates, each with two technical replicates in MS-5 co-culture (N = 3 for the non-
MS5 data, N = 6 for the MS5 data). Error bars show standard deviation. All comparisons 
were made with paired sample T-tests. **: P < 0.01; ***: P < 0.001. 
 


SUPPLEMENTAL PATIENT CASE HISTORIES 
 
Patient 1 is a 33-year-old male. He was diagnosed with congenital non-spherocytic hemolytic 
anemia at 3 years of age. At the time, he suffered from progressive fatigue and jaundice. There 
is no documented history of perinatal ascites. He suffers from severe hyperbilirubinemia (in 
part due by co-inheritance for Gilbert’s syndrome) and hepatosplenomegaly. He underwent 
cholecystectomy at an unknown date. At 17 years of age, he was diagnosed with secondary 
hemochromatosis, for which he undergoes monthly phlebotomies. The diagnosis of hereditary 
xerocytosis (HX) was first established through osmotic gradient ektacytometry (which 
displayed the characteristic left shift) and increased osmotic resistance of the red blood cells. 
This diagnosis was later confirmed by DNA sequence analysis of PIEZO1 (displaying 
heterozygosity for c.6262C>G, p.Arg2088Gly1). Regarding information on the patient’s family 
history, both the brother and the father of the patient also suffer from HX (not studied). The 
patient’s mother is normal at both the clinical and hematological levels. 
 
Patient 2 is a 23-year-old female. She presented with fatigue, abdominal pain, pallor and 
jaundice at 6 years of age. At the time, her hemoglobin levels were low to normal and she 
displayed signs of mild Coombs-negative hemolysis (reticulocytosis, increased bilirubin levels 
and increased osmotic resistance), mild hepatomegaly and no splenomegaly. There is no 
documented history of perinatal ascites. She underwent cholecystectomy at 8 years of age 
and was splenectomized at 12 years of age due to hemolytic anemia. Her clinical parameters 
improved at the time, but she developed deep venous thrombosis at 15 years of age and again 
at 18 years of age. She is currently clinically well and displays compensated hemolysis, 
without anemia. The diagnosis of HX was established when she was 16 years old through 
osmotic gradient ektacytometry (which displayed the characteristic left shift) and later 
confirmed by DNA sequence analysis of PIEZO1 (displaying heterozygosity for c.7367G>A, 
p.Arg2456His2). Regarding information on the patient’s family history, she comes from a large 
family with many affected family members over the course of 3 generations. These family 
members include Patient 3 (aged 47) and Patient 10 (aged 18). The former is an uncle of 
Patient 2, whilst the latter is her nephew. Patient 3 and Patient 10 were diagnosed with HX 
only as a result of the diagnosis of Patient 2. Both osmotic gradient ektacytometry 
measurements displayed the typical left shifted curve. Until then, they had not been diagnosed 
with hemolytic anemia; however, Patient 10 was known to suffer from severe iron overload 
and consequent organ damage (liver), for which he was phlebotomized. No documented 
history of perinatal ascites was reported for either Patient 3 or Patient 10. Upon molecular 
diagnosis, both Patient 3 and Patient 10 displayed the same PIEZO1 pathological variant, 
c.7367G>A (p.Arg2456His2). 
 
Patient 4 is a 19-year-old male. Unfortunately, comparatively little information is known about 
this patient’s clinical history. He was diagnosed with HS-like hemolytic anemia at 12 years of 
age and underwent splenectomy at 16 years of age (presumably due to his HS-like hemolytic 
anemia). Osmotic gradient ektacytometry displayed a slightly left-shifted curve, and the same 
feature was observed in his clinically unaffected father. DNA sequence analysis of PIEZO1 
displayed heterozygosity for a c.1792G>A (p.Val598Met3) mutation in both the patient and his 
father. To date, the patient has not experienced any thrombotic events. 
 
Patient 5 (and Patient 6, which corresponds to the second visit of Patient 5 to the clinic) is a 
47-year-old female. A detailed clinical history of Patient 5 has previously been reported by 
Fermo E et al.4 
 
Patient 7 is a 55-year old female. The patient was asymptomatic until 24 years of age, when 
fatigue and abdominal pain developed accompanied by mild chronic macrocytic hemolytic 
anemia with reticulocytosis and splenomegaly. At the time, the patient was diagnosed with 
hereditary spherocytosis. There is no documented history of perinatal ascites. The patient was 
re-evaluated at 53 years of age due to exacerbation of the anemia and fatigue. At that point, 
the patient displayed the following hematological parameters: hemoglobin 9.1 g/dL, mean cell 
volume (MCV) 106.5 fL, absolute reticulocyte number 104x109/L, unconjugated bilirubin 3.01 
mg/dL, consumed haptoglobin and increased serum ferritin levels 1464 ng/mL. The EMA 
binding test results, red cell membrane protein content, and red cell enzyme activities were 
normal, thus excluding a cytoskeletal or metabolic defect. Bone marrow evaluation showed 
mild signs of dyserythropoiesis. Finally, osmotic gradient ektacytometry displayed the 
characteristic left shift suggestive of HX, which was later confirmed by an NGS targeted 
sequencing panel which displayed the presence of heterozygosity for c.1792G>A, 
p.(Val598Met3) in the PIEZO1 gene.  
 
Patient 8 is a 46-year-old male. He suffered from neonatal jaundice at birth, with no signs of 
hemolysis until 18 years of age. He underwent cholecystectomy at 15 years of age due to the 
presence of gallstones, at which point splenomegaly was also detected. An extensive 
hematological investigation for chronic hemolytic anemia was performed when the patient was 
28 years old, displaying the following hematological parameters: hemoglobin 14.2 g/dL, MCV 
100 fL, absolute reticulocyte number 899x109/L, consumed haptoglobin and increased 
unconjugated bilirubin 22.4 mg/dL (which was later justified by a diagnosis of concomitant 
Gilbert’s syndrome). Osmotic fragility tests, red blood cell membrane protein content and 
enzyme activity displayed normal results, thus excluding a cytoskeletal or metabolic defect. 
The patient was diagnosed with HX more recently, following osmotic gradient ektacytometry 
(which displayed the characteristic left shift) and molecular investigation that showed the 
presence of a known pathogenic variant, c.7367G>A (p.Arg2456His2), in PIEZO1. Neither 
parent displayed anemia; however, the father (not studied) suffered from jaundice, increased 
bilirubin levels and reticulocytosis. 
 
Patient 9 is a 43-year-old female and is the sister of Patient 8. She underwent clinical 
investigation for the first time at the age of 25 due to being subjected to cholecystectomy 
(performed due to the presence of gallstones). Mild macrocytic hemolytic anemia was 
observed at the time, with the following hematological parameters: hemoglobin 10.7g/dL, MCV 
112.8 fL, absolute reticulocyte number 371x109/L, unconjugated bilirubin 9.2 mg/dL 
(concomitant Gilbert’s syndrome), consumed haptoglobin and normal serum ferritin levels. 
Osmotic fragility test results, red cell membrane protein content and RBC enzyme activities 
were normal, thus excluding a cytoskeletal or metabolic defect. Similarly to Patient 8, the 
diagnosis of HX was performed more recently following osmotic gradient ektacytometry (which 
displayed the characteristic left shift) and molecular investigations that showed the presence 
of a known pathogenic variant, c.7367G>A (p.Arg2456His2), in PIEZO1.  
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Supplemental Figure 1 – Ektacytometry-based analysis of red blood cells from hereditary xerocytosis patients
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 2 – Yoda1-induced calcium entry displays a 
concentration-response relationship in erythrocytes 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 3 – Inhibition of calcineurin does not correct the delayed reticulocyte maturation of HX patients 
 
 
SUPPLEMENTAL FIGURE LEGENDS 
 
Supplemental Figure 1 – Ektacytometry-based analysis of red blood cells from 
Hereditary Xerocytosis patients 
Scatter plots of cross-sectional area plotted against the deformability index (as measured by 
dividing cell length by cell width), visualizing erythrocytes (CD71 negative) and reticulocytes 
(CD71 positive) from HX patients (annotated by patient number as per Table 1 in the main 
manuscript file) separated by splenectomy status and compared to healthy reference samples 
(Ctrl). Cells were analyzed through use of the Automated Rheoscope and Cell Analyzer, with 
a minimum of 1000 cells measured per sample.  
 
Supplemental Figure 2 – Yoda1-induced calcium entry displays a concentration-
response relationship in erythrocytes 
Flow cytometry histograms plotting cell count against Fluo-4 AM signal (525 nm, FITC channel) 
upon erythrocyte exposure to varying concentrations of Yoda1, a chemical inducer of Piezo1 
activity. Fluo-4 AM serves as an indicator of the calcium concentration inside of the cell. A 
minimal effect on calcium entry occurs at 0.156 µM and becomes evident at 0.625 µM. 
Conversely, Yoda1-mediated calcium entry becomes saturated at concentrations above 5 µM. 
 
Supplemental Figure 3 – Inhibition of calcineurin does not correct the delayed 
reticulocyte maturation of HX patients 
Mean CD71/TO loss in reticulocytes from healthy donors and HX patients, cultured alone 
(dashed line) or in co-culture with MS-5 cells (solid line) and normalized against the CD71-/TO- 
percentage observed in the final timepoint of the respective healthy control samples. HX 
patients were either left untreated or were treated with 100 nM FK506/Tacrolimus, a calcineurin 
inhibitor (IC50: 1-3 nM). A paired two-tailed T-test comparison between untreated and FK506-
treated patient samples resulted in P-values of 0.514 and 0.396 for cells cultured alone and in 
co-culture with MS-5 cells, respectively. 
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